Abstract | OBJECTIVE: METHODS: Relative expression of IGF-2 was measured in 109 epithelial ovarian cancers and eight normal ovarian surface epithelial (NOSE) samples, using quantitative real-time polymerase chain reaction. Associations with clinicopathological parameters were examined. RESULTS: Expression of the IGF-2 gene was more than 300-fold higher in ovarian cancers compared with normal ovarian surface epithelium samples (P <0.001). High IGF-2 expression was associated with advanced stage disease at diagnosis (P <0.001), high-grade cancers (P <0.05) and sub-optimal surgical cytoreduction (P = 0.08). In multivariate analysis, relative IGF-2 expression was an independent predictor of poor survival. CONCLUSIONS: Expression of the IGF-2 gene is significantly higher in ovarian cancers relative to normal ovarian surface epithelium. Further, high IGF-2 gene expression is associated with high grade, advanced stage disease, and is an independent predictor of poor survival in patients with epithelial ovarian cancer. As such, IGF-2 is a molecular marker and potential therapeutic target for the most aggressive epithelial ovarian cancers.
|
Authors | Robyn A Sayer, Johnathan M Lancaster, Jennifer Pittman, Jonathon Gray, Regina Whitaker, Jeffrey R Marks, Andrew Berchuck |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 96
Issue 2
Pg. 355-61
(Feb 2005)
ISSN: 0090-8258 [Print] United States |
PMID | 15661221
(Publication Type: Journal Article)
|
Chemical References |
- Insulin-Like Growth Factor II
|
Topics |
- Cystadenocarcinoma, Serous
(genetics, metabolism, pathology)
- Female
- Gene Expression
- Humans
- Insulin-Like Growth Factor II
(biosynthesis, genetics)
- Ovarian Neoplasms
(genetics, metabolism, pathology)
- Predictive Value of Tests
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Rate
|